<div id="readability-page-1"><p>Cryoport, Inc. (NASDAQ:CYRX - Get Free Report) shares traded down 6.8% during mid-day trading on Tuesday . The company traded as low as $10.49 and last traded at $10.49. 35,269 shares were traded during trading, a decline of 93% from the average session volume of 473,428 shares. The stock had previously closed at $11.25.</p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities analysts have recently issued reports on the stock. Jefferies Financial Group began coverage on shares of Cryoport in a research report on Thursday, April 4th. They set a &#34;buy&#34; rating and a $21.00 target price on the stock. B. Riley downgraded Cryoport from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and cut their price target for the stock from $22.00 to $19.00 in a research note on Friday, May 3rd. Stephens reaffirmed an &#34;equal weight&#34; rating and set a $17.00 price target on shares of Cryoport in a research note on Wednesday, March 13th. Needham &amp; Company LLC restated a &#34;buy&#34; rating and issued a $18.00 target price on shares of Cryoport in a report on Wednesday, May 8th. Finally, UBS Group upped their target price on shares of Cryoport from $14.50 to $17.00 and gave the company a &#34;neutral&#34; rating in a report on Friday, March 15th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and an average target price of $18.25.</p><p><b>Read Our Latest Analysis on Cryoport</b></p><h2>Cryoport Price Performance</h2><p>The company has a debt-to-equity ratio of 0.86, a current ratio of 10.73 and a quick ratio of 10.22. The company's 50-day simple moving average is $14.51 and its 200-day simple moving average is $15.29. The company has a market cap of $498.97 million, a price-to-earnings ratio of -4.25 and a beta of 1.64. </p><p>Cryoport (NASDAQ:CYRX - Get Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). The business had revenue of $54.59 million for the quarter, compared to analysts' expectations of $58.78 million. Cryoport had a negative net margin of 50.17% and a negative return on equity of 15.19%. The business's quarterly revenue was down 13.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.16) earnings per share. On average, equities research analysts anticipate that Cryoport, Inc. will post -1.35 EPS for the current year. </p><h2>Insider Activity</h2><p>In related news, CEO Jerrell Shelton sold 57,039 shares of Cryoport stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $15.30, for a total transaction of $872,696.70. Following the transaction, the chief executive officer now directly owns 634,352 shares of the company's stock, valued at $9,705,585.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, Director Richard J. Berman sold 8,105 shares of the firm's stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $13.41, for a total value of $108,688.05. Following the transaction, the director now directly owns 100,000 shares of the company's stock, valued at approximately $1,341,000. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jerrell Shelton sold 57,039 shares of Cryoport stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $15.30, for a total value of $872,696.70. Following the completion of the transaction, the chief executive officer now directly owns 634,352 shares in the company, valued at $9,705,585.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 79,228 shares of company stock valued at $1,199,908. Company insiders own 10.10% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently added to or reduced their stakes in the business. Comerica Bank increased its position in Cryoport by 73.0% in the 1st quarter. Comerica Bank now owns 3,481 shares of the company's stock worth $62,000 after buying an additional 1,469 shares during the period. Natixis Investment Managers International increased its position in Cryoport by 61.5% in the 4th quarter. Natixis Investment Managers International now owns 4,536 shares of the company's stock worth $70,000 after buying an additional 1,727 shares during the period. Lazard Asset Management LLC increased its position in Cryoport by 294.3% in the 1st quarter. Lazard Asset Management LLC now owns 5,378 shares of the company's stock worth $95,000 after buying an additional 4,014 shares during the period. WINTON GROUP Ltd bought a new position in Cryoport in the 3rd quarter worth approximately $163,000. Finally, Pathstone Family Office LLC bought a new position in Cryoport in the 3rd quarter worth approximately $165,000. 92.90% of the stock is owned by institutional investors. </p><h2>Cryoport Company Profile</h2> (Get Free Report)<p>Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Cryoport</li><li>Energy and Oil Stocks Explained</li><li>Top 3 High-Yield Stocks with Strong Analyst Ratings</li><li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li><li>3 Stocks to Watch: Chip Shortage Impact on Industries</li><li>Market Cap Calculator: How to Calculate Market Cap</li><li>Dividend King ABM Industries is on Track for New Highs</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ The Greatest LEGAL Transfer of Wealth in History is Underway <span><span>(From Stansberry Research)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MzA2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MzA2"/></p><h2>Should you invest $1,000 in Cryoport right now?</h2><p>Before you consider Cryoport, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.</p><p>While Cryoport currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

CYRX

<p>Cryoport (NASDAQ:CYRX) shares traded down 6.8% during mid-day trading. Analysts have issued reports on the stock, with an average rating of "Hold" and an average target price of $18.25. The company reported lower than expected earnings for the quarter. Insiders have sold a significant amount of company stock. Institutional investors have made changes to their stakes in the business.</p>

Cryoport (NASDAQ:CYRX) Shares Down 6.8%